Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2013 Mar 31;71(6):1531–1540. doi: 10.1007/s00280-013-2152-7

Table 2.

Patient demographics (N=56)

Characteristic n (%)
Age – years, mean (SD) 63.7 (11.6)
Gender
    Male 34 (60.7)
    Female 22 (39.3)
Race
    White 41 (73.2)
    Other 15 (26.8)
Diabetes
    Yes 47 (83.9)
    No 9 (16.1)
Marital status
    Married 43 (76.8)
    Not married 13 (23.2)
Education level
    High school or less 11 (19.6)
    Greater than high school 45 (80.4)
Chemotherapy regimen
    Bortezomib-based 50 (89.3)
    No bortezomib 6 (10.7)
Chemotherapy cycles at baseline
    <1 cycle 13 (23.2)
    1-2 cycles 43 (76.8)
Total chemotherapy cycles
    <5 cycles 41 (73.2)
    5 cycles 15 (26.8)

SD Standard Deviation